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Abstract
We conducted a systematic review of randomised controlled trials (RCT) of increased intake of arachidonic acid (ARA) on fatty acid status and
health outcomes in humans. We identified twenty-two articles from fourteen RCT. Most studies were conducted in adults. These used between
80 and 2000 mg ARA per d and were of 1–12 weeks duration. Supplementation with ARA doses as low as 80 mg/d increased the content of
ARA in different blood fractions. Overall there seem to be fewmarked benefits for adults of increasing ARA intake from the typical usual intake of
100–200mg/d to asmuch as 1000mg/d; the few studies using higher doses (1500 or 2000mg/d) also report little benefit. However, theremay be
an impact of ARA on cognitive and muscle function which could be particularly relevant in the ageing population. The studies reviewed here
suggest no adverse effects in adults of increased ARA intake up to at least 1000–1500 mg/d on blood lipids, platelet aggregation and blood
clotting, immune function, inflammation or urinary excretion of ARAmetabolites. However, in many areas there are insufficient studies to make
firm conclusions, and higher intakes of ARA are deserving of further study. Based on the RCT reviewed, there are not enough data to make any
recommendations for specific health effects of ARA intake.
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Arachidonic acid (ARA) is the common name for all-cis-
5,8,11,14-eicosatetraenoic acid (Fig. 1), commonly abbreviated
to 20 : 4ω-6 or 20 : 4n-6. ARA is a long-chain PUFA (LC-PUFA)
within the n-6 family. ARA is commonly found in cell mem-
branes, particularly in animals. Therefore meat, especially red
meat, and also white meat and fish; offal (organ meat) like liver,
kidney and brain; and eggs are sources of ARA. A recent study
reported estimated dietary intakes for ARA among adults in
47 developed and 128 developing countries(1); the study
reported that 48 % of the 175 countries have an ARA intake
Abbreviations: ARA, arachidonic acid; CE, cholesteryl ester; DGLA, dihomo-γ-linolenic acid; FA, fatty acid; LA, linoleic acid; LC-PUFA, long-chain
PUFA; PL, phospholipid; RCT, randomised controlled trial.
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of <150 mg/d. Amongst the developed countries, mean daily
ARA intakes were estimated to be between 100 and 350 mg
and ARA contributed <0·1 % of total daily energy intake. Data
on ARA intake in specific population subgroups are extremely
limited(2). Human milk also contains ARA. Brenna et al.(3)
reported human milk ARA (as percentage of total fatty acids
(FA)) from 106 studies in the range of 0·24–1 % with a median
of 0·47 (SD 0·13) %. Many infant formulas are supplemented with
ARA at a level of 0·35–0·7 % of total FA.
ARA can be synthesised from the essential n-6 PUFA linoleic
acid (18 : 2n-6, LA) by a series of desaturation and elongation
reactions as shown in Fig. 2. Based upon a studywith 2H-labelled
LA, Emken et al.(4) reported that 1–2·2 % of LA is converted
to other n-6 PUFA in healthy young adult males with about
0·5 % appearing as ARA.
Despite its relatively low intake from the diet, ARA makes an
important contribution to FAwithin circulating lipids and inmost
cells and tissues, particularly to membrane phospholipids (PL).
For example, ARA has been reported to contribute an
average of 9·6, 6·6, 15·5, 9·5 and 16 % of total FA in plasma phos-
phatidylcholine, plasma cholesteryl esters (CE), erythrocytes,
platelets and blood mononuclear cells in healthy British adults
who were non-oily-fish consumers and were consuming typical
diets(5). The relatively high content of ARA in these pools, in com-
parison with its intake from the diet, suggests that synthesis from
LA is an important pathway and that metabolic mechanisms
might serve to concentrate and retain ARA in cell membranes.
ARA has a structural role in the brain(6,7), free ARA has roles in
cell signalling, and ARA-containing PL also have roles in cell sig-
nalling and are precursors to endocannabinoids that have a
range of biological properties(8). A major role of cell membrane
ARA is as a substrate for the synthesis of eicosanoids, which
include prostaglandins, thromboxanes and leukotrienes. These
are formed by metabolism of ARA by cyclo-oxygenase, lipoxy-
genase and cytochrome P450 pathways(9–11). The resulting
metabolites have many roles in inflammation and pain, regula-
tion of the immune response, bone turnover, platelet aggrega-
tion and blood clotting, smooth muscle contraction and renal
function(9–11). These well-known functions of ARA-derived
metabolites suggest that ARA itself might impact a range of out-
comes related to human health. This has been explored in a
small number of human studies, frequently using supplements
containing ARA. The first such study was by Seyberth et al.(12).
This was a small study involving four healthy men given 6 g
of ethyl arachidonate daily for a period of 2–3 weeks. The
authors identified an increased content of ARA in plasma
TAG, PL and CE and in platelets, and a mean 47 % increase in
excretion of the major urinary metabolite of ARA. The threshold
of ADP required to induce platelet aggregation was decreased in
all four subjects (by 40–90 %), which was interpreted as an
enhanced potential for blood clotting. This was considered to
be a major health concern and most likely explains why there
was no further interest in studies with ARA supplements in
humans until the mid-1990s(13–17).
The aim of this systematic review is to assess the effects of
increasing ARA intake through foods or supplements on ARA
levels in different compartments, metabolism and health-related
outcomes in humans. All health-related outcomes that have been
addressed in randomised controlled trials (RCT) investigating
increased ARA intake through foods or supplementation were
considered. Research gaps were identified and we assessed
whether recommendations for ARA intake can be made for spe-
cific health effects.
Methods
Details of the methods used for the systematic review are
published in the PROSPERO international prospective register
of systematic reviews (registration number: CRD42017076493).
Criteria for considering studies in this review
Types of study. RCT in humans were included if they measured
any human health-related outcome. Observational and non-
randomised interventional studies were excluded.
Types of intervention. Studies were included if they increased
intake of ARA through a food or supplement and had a control
group with either a lower ARA intake or no ARA supplementa-
tion. We excluded studies assessing the effect of the combina-
tion of DHA and ARA or the combination of any other FA
with ARA.
Fig. 1. Structure of arachidonic acid. The numbers 1, 5, 8, 11 and 14 beneath
the hydrocarbon chain refer to carbon number counting from the α end of
the chain. The numbers 1 and 6 above the hydrocarbon chain refer to carbon
number counting from the ω end of the chain.
Fig. 2. Outline of the pathway of biosynthesis and further metabolism of
arachidonic acid.
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Types of population. Studies of human subjects (infants, chil-
dren and adults) conducted in any country were included, with-
out restriction on age or health status. We excluded animal and
in vitro studies.
Minimum duration of intervention. Duration of ARA interven-
tion and follow-up varied depending on the study design and
health outcome measured; we did not place a restriction on this.
Types of outcome measure. All types of health outcomes,
including risk markers of disease, were included.
Date of publication: There was no restriction on study inclu-
sion according to the year of publication.
Search methods for identification of studies
The Cochrane Central Register of Controlled Trials database was
searched on 23 August 2017 and again on 23 March 2018 in an
update search, using text words with appropriate truncation and
relevant indexing terms (Table 1). The keywords for the search
were different synonyms related to the intervention (i.e. ARA).
The systematic review software Covidence (www.covidence.
org) was used to facilitate screening of the literature. Titles
and/or abstracts of studies retrieved using the search strategy
were screened independently by two review authors (a combi-
nation of S. L., A. S., R. P. M., M. F. and B. S.) to identify studies
that met the inclusion criteria. The full texts of the potentially eli-
gible studies were retrieved and independently assessed for eli-
gibility by two review team members (a combination of S. L., A.
S., R. P. M. and B. S.) with final agreement by all authors. Any
disagreement between them over the eligibility of particular
studies was resolved through discussion between the two rel-
evant reviewers or the whole group. A standardised, pre-piloted
form was used to extract data from the included studies for
assessment of study quality and evidence synthesis. Extracted
information included study setting; study population and partici-
pant demographics and baseline characteristics; details of the
intervention and control conditions; study methodology; recruit-
ment and study completion rates; outcomes and times of
measurement; and funding. One of the authors (B. v. d. H.,
R. P. M., M. F. or B. S.) extracted data and the data were
Table 1. Search terms used for the Cochrane Central Database search
1 exp Arachidonic Acid/ (18143)
2 arachidonic acid*.mp. (46543)
3 arachidonate*.mp. (11283)
4 eicosatetraenoic acid*.mp. (3825)
5 eicosatetranoic acid*.mp. (22)
6 20 : 4 n-6.mp. (932)
7 20 : 4n-6.mp. (986)
8 20 : 4n6.mp. (101)
9 or/1–8 (53238)
10 randomi?ed controlled trial.pt. (469845)
11 controlled clinical trial.pt. (94452)
12 randomi?ed.ab. (411841)
13 placebo.ab. (191566)




18 exp animals/ not humans.sh. (4442323)
19 17 not 18 (1063843)
20 9 and 19 (1502)
Fig. 3. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart of study selection.
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Table 2. Characteristics of the included articles
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Table 2. (Continued )
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double-checked by another member in the team. A flow chart of
the literature identification can be found in Fig. 3.
Reference lists of all the eligible papers and relevant system-
atic reviews were searched for additional studies.
Risk of bias assessment
Three authors independently (R. P. M., M. F. and B. S.) assessed
the risk of bias in included studies by following the Cochrane
Risk of Bias guidelines(18), and any disagreement between them
was resolved through discussion.
Results
CENTRAL search
A total of 2104 titles and abstracts were identified via the elec-
tronic search from which 1255 duplicates were removed.
Additional references (n 69) were found via reference screening
of review papers found in the electronic search, of which thirty-
six were duplicates. In total, 1964 titles were excluded as irrel-
evant based on title and abstract considering the inclusion and
exclusion criteria. The remaining forty-eight papers were
screened based on full text, and twenty-two were considered
as relevant for review inclusion. A flow chart of the literature
identification process can be found in Fig. 3. The twenty-two
articles included in the systematic review(13–17,19–35) came from
fourteen individual studies. Table 2 summarises these studies.
Most studies were conducted in healthy young or older adults
and several were restricted to men. One study was conducted
in breast-feeding women, one in patients with liver cirrhosis
and two in children with parasitic worm infestation. Studies in
adults used between 80 and 2000 mg ARA per d, were of
1–8 weeks duration and usually used ARA as a supplement.
Risk of bias assessment
The overall risk of bias analysis shows that for many studies bias
is unclear due to insufficient reporting of required details essen-
tial for an informed decision (Fig. 4).
Fatty acid composition in different compartments. A number
of included studies reported the effect of increased intake of ARA
on the FA composition of one or more blood pools.
Nelson and colleagues(13–17) performed a placebo-controlled,
random order, cross-over study in twelve healthy male partici-
pants housed in a metabolic unit. Participants consumed a stabi-
lisation diet that contained about 200 mg/d ARA for 15 d, and
then either continued on the stabilisation diet for 50 d or con-
sumed a diet that provided 1·7 g/d ARA for 50 d. After that,
the participants crossed over to the other diet for 50 d, followed
by 15 d of the stabilisation diet. Ten participants completed the
study. The FA compositions of plasma, plasma TAG, CE, PL and
NEFA, erythrocytes, adipose tissue(14) and platelets(13) were
reported. There was a near doubling of plasma ARA when
ARA was consumed (approximately from 8 to 16 % of total
FA) which was accompanied by a decrease in LA. ARA increased
in plasma TAG, CE (approximately from 7·5 to 15 % of FA) and
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expense of LA. Therewas a small increase in ARA in erythrocytes
and platelets but no change in adipose tissue ARA. Increases in
ARA content were not reflected in any changes in EPA or DHA,
except in erythrocytes where DHA content decreased.
Thies et al.(33–35) performed a placebo-controlled, rando-
mised, parallel study in healthy older British subjects: eight par-
ticipants received a blend of palm and sunflower seed oils as
control, while eight received approximately 700 mg ARA (from
ARASCO) daily for 12weeks. Participant’s habitual intake of ARA
was about 150 mg/d. Blood samples were collected at baseline
and at 4, 8 and 12weeks supplementation and then after 4weeks
washout. The FA compositions of plasma PL(33) and bloodmono-
nuclear cells(34) were reported. In plasma PL, ARA increased
from 9·3 to 16 % of FA by 4 weeks and did not increase further,
but returned to baseline levels after 4 weeks washout(33). Plasma
PL ARA levels were significantly higher in the ARA group than in
the control group at weeks 4, 8 and 12. The increase in ARA in
plasma PL did not significantly affect LA, EPA and DHA levels. In
mononuclear cells, ARA increased significantly from approxi-
mately 20 % of total FA at baseline to approximately 23 % at 8
and 12 weeks(34). This increase was mainly compensated for
by a decrease in LA. EPA and DHA levels in mononuclear cells
were not affected by ARA supplementation. ARA levels in mono-
nuclear cells were not significantly different between the ARA
and control groups.
Pantaleo et al.(28) evaluated if ARA supplementation could
increase ARA levels in plasma and erythrocyte lipids in Italian
patients with liver cirrhosis. Patients received either 2 g ARA
(as 4 g ARASCO) daily or oleic acid as control for 8 weeks.
ARA supplementation for 8 weeks significantly increased ARA
levels in plasma total lipids, plasma PL and erythrocytes.
This increasewas transitory, since ARA levels returned to baseline
4 weeks after cessation of supplementation. No changes in ARA
levels were observed in the control group. There was no signifi-
cant effect of ARA on LA in plasma total lipids, plasma PL or eryth-
rocytes, although LAwas numerically lower in all three pools after
ARA compared with before. No results were given for n-3 FA
levels, and no between-group comparison was made.
Schubert et al.(30) compared the effect of two different fat
blends on the FA status of thirty healthy German adults.
Participants were randomly distributed into two groups receiving
for 2 weeks either an oil blend providing 240 mg/d of α-
linolenic acid, 120 mg/d of EPA, 49 mg/d of stearidonic acid
and 73 mg/d of γ-linolenic acid in three capsules per d or an
oil providing 40mg ARA per d in one capsule per d plus two olive
oil capsules per d. Results showed that 40 mg/d ARA supplemen-
tation for 2 weeks did not increase plasma or erythrocyte ARA.
This lack of change is most likely because of the low amount
of ARA provided. Between-group comparison, done at each time
point, showed that EPA was higher in plasma lipids after the 2
weeks supplementation period in the group receiving the blend
containing EPA than in the ARA group.
Kusumoto et al.(25) carried out a double-blind, placebo-
controlled study in healthy Japanese men consuming a high fish
diet. One group of men received capsules providing 838 mg ARA
incorporated into a TAG derived from Mortierella alpina
(SUNTGA40S) daily for 4 weeks, while another group received
capsules with olive oil as control. FA in serum PL and TAG were
measured in fasted blood at four time points: baseline, after 2 and
4 weeks of supplementation and 4 weeks after the end of supple-
mentation. Supplementation with ARA increased ARA content of
serum PL from 9·6 to 13·7 (after 2 weeks) and 13·9% (after
4 weeks) of total FA, which was significantly different from
baseline, and then ARA content decreased to a level close to that
























Mitchell et al.(27); 
Markworth et al.(28)
Nelson et al.(13, 14); 







Thies et al.(34–36) 
Reference 
Fig. 4. Risk of bias analyses. Under ‘other bias’ power analyses, statistical shortcomings (e.g. only within-treatment comparisons) and experimental design issues were
considered. Legend: green: low risk of bias; red: high risk of bias; orange: unclear risk of bias.
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of baseline 4 weeks after the end of supplementation. Serum PL
ARA did not change in the control group. The same pattern was
observed in serumTAG, although levels of ARAwere lower in this
lipid class than in PL. Between-group comparison showed a sig-
nificantly higher ARA content in serum PL, but not in serum TAG,
in the group supplemented with ARA than in the control group,
after 2 and 4 weeks supplementation. In serum PL, LA was signifi-
cantly lower than baseline after 2 and 4 weeks ARA supplemen-
tation, while it was unchanged in the control group and in serum
TAG. Between-group comparison showed no significant differ-
ence in LA in serum PL or TAG. There was no significant change
in plasma PL or TAG EPA and DHA. This study shows that in a
healthy male adult population with high fish intake (approxi-
mately 860 mg EPA+DHA intake per d) and a basal intake
of approximately 177 mg ARA per d, supplementation with
838 mg/d is able to increase ARA levels in serum PL without
compromising EPA and DHA levels.
Ishikura et al.(23) supplemented the habitual diet of Japanese
elderly men with three capsules per d providing either 240 mg
ARA in the form of ARA-enriched TAG (SUNTGA40S; 600 mg
oil) or control (600 mg olive oil per d) for 1 month. ARA supple-
mentation significantly increased ARA content in serum
PL (from 140 μg/ml serum to 175 μg/ml serum; this was
equivalent to an increase from 8·7 to 10·7 % of FA), and signifi-
cantly decreased EPA but did not affect DHA. In the control
group, there was no change in ARA, EPA or DHA levels. No
between-group comparison was made.
Hirota et al.(22) performed a double-blind, random order
cross-over, placebo-controlled intervention study with twenty-
three young Japanese women aged 18–23 years. The subjects
received one 200 mg capsule daily, either containing a low dose
of ARA (approximately 80 mg per d in 200 mg ARA enriched-
TAG) or olive oil as control. The study duration was 12 weeks
in total, including four successive periods of 3 weeks: 3 weeks
washout, 3 weeks with treatment 1, 3 weeks washout and 3
weekswith treatment 2. The participantswere asked to limit their
fish consumption to a maximum of four times per week. They
recorded their food intake throughout the study, allowing their
FA intake at the beginning and at the end of the two treatment
periods to be estimated. Fasted bloodwas taken at the beginning
(baseline value) and at the end of the two 3-week treatment peri-
ods, and FA were analysed in erythrocyte and plasma PL, TAG
and CE. ARA supplementation significantly increased ARA and
total n-6 LC-PUFA levels in the four blood pools compared with
olive oil, without decreasing n-3 LC-PUFA, except for a signifi-
cant decrease in n-3 LC-PUFA in plasma CE. This study
shows that in a female population with relatively high fish intake
(460–560 mg EPAþDHA intake per d) and a basal intake of
approximately 150 mg ARA per d, supplementation with a small
dose of ARA (approximately 80 mg/d) is able to significantly
increase ARA levels in erythrocyte and plasma fractions without
compromising n-3 LC-PUFA levels.
Kakutani et al.(24) performed a double-blind, parallel,
placebo-controlled intervention study in 118 healthy Japanese
elderly who were not supplement consumers. They received
ten 170 mg capsules daily, either containing a low dose or a high
dose of ARA (total of approximately 240 mg or approximately
720 mg/d) as an ARA enriched-TAG (SUNTGA40S) or olive oil
as control for 4 weeks, followed by a 4-week washout period.
The participants recorded their food intake throughout the study,
allowing to calculate their FA intake at the baseline and after 4
weeks of supplementation. FA in plasma PL were measured in
fasted blood at four time points: baseline, after 2 and 4 weeks
of supplementation and 4 weeks after the end of supplementa-
tion. Supplementation with 240 and 720 mg/d of ARA increased
ARA content of plasma PL by 2·5 % and 5·6 % of total FA, respec-
tively, which was significantly different from baseline, and then
ARA decreased to a level close to that of baseline 4 weeks after
the end of supplementation. Plasma ARA did not increase in the
control group. Between-group comparison was done but not
clearly reported. The ARA increase in plasma PL was dose de-
pendent, at least up to 720 mg/d. In the high ARA group, plasma
PL LAwas significantly lower than at baseline after 2 and 4weeks
supplementation, while it was unchanged in the low ARA and
the control groups. There was no significant change in plasma
PL EPA and DHA. This study shows that in an elderly population
with high fish intake (853–1176 mg EPAþDHA intake per d)
and a basal intake of approximately 170 mg ARA per d, supple-
mentation with a 240 or 720 mg/d is able to dose-dependently
increase ARA levels in plasma PL without compromising EPA
and DHA levels.
Recently Markworth et al.(27) reported from a RCT of 1500 mg
ARA per d for 4 weeks in youngmen participating in a resistance
training programme. FAweremeasured in plasma and in skeletal
muscle at the start and end of the supplementation period.
Plasma ARA increased from 8·4 to 16·2 % of total FA and was
higher in the ARA group than in the control group at the end
of the intervention. Plasma LA decreased from 25 to 14 % of total
FA in the ARA group. Plasma EPA decreased slightly in the ARA
group but was not different between groups at week 4. Plasma
DHA was not significantly altered. Skeletal muscle ARA
increased from 12 to 14·6 % of total FA but this was not a signifi-
cant effect.
Smit et al.(32) performed a randomised, open intervention
study in twenty breast-feeding Israeli women. The women’s
mean age was 23 years and the lactation duration ranged
between 3 and 10 months. The ARA group received 284 mg
ARA per d (0·8 ml ARA-rich oil), while the control group did
not receive any supplement. The study duration was 1 week,
during which three milk samples were taken (before, after 1 d
and after 7 d supplementation). Milk FA were analysed and
the FA composition of the two groups was compared at the three
time-points. It was found that women in the ARA group had the
same content of ARA in their milk as womenwho did not receive
any supplement. Other long chain n-6 PUFA and DHA did not
differ either, while EPA was significantly lower in the ARA group
at day 7. This small study suggests that in a population of lactat-
ing women with a habitual estimated ARA intake of approxi-
mately 200 mg/d, a supplement of approximately 300 mg ARA
per d does not significantly affect milk ARA (or DHA), but does
lower milk EPA. This effect can be observed after 1 week of ARA
supplementation.
In Egyptian schoolchildren infected with Schistosoma man-
soni, ARA (10mg/kg bodyweight per d for 5 d in each of 3weeks)
significantly increased plasma ARA from 7·9 to 12·1 % of total FA,
with no significant effect on LA(19).
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In summary, increased ARA intake significantly increases the
ARA content in different blood fractions, including erythrocytes,
platelets and mononuclear cells, with doses as low as 80 mg/d
being effective. The low dose of 40 mg ARA per d did not affect
ARA level in plasma or erythrocytes of healthy adults. It is likely
that enrichment of ARA in different compartments and pools is
dose dependent. Fig. 5 shows data for serum and plasma PL from
seven studies and indicates a near linear dose-dependent
increase in ARA content up to an intake of about 1000 mg/d.
Lack of studies using higher intakes of ARA and the short dura-
tion of most studies performed to date limit a full understanding
of this dose–response relationship. A study specifically designed
to assess the dose–response relationship is required to be certain
about the exact nature of this relationship. EPA was decreased in
several studies (humanmilk with 300mg/d ARA, plasma CEwith
80 mg/d ARA, serum PL with 240 mg/d ARA and plasma with
1500mg/d ARA) and one study reported a decrease in DHA con-
tent of erythrocytes when a high dose (1·7 g/d) of ARA was con-
sumed for 50 d.
Effect of arachidonic acid on PUFA metabolism
A small sub-study(21) within the larger study by Nelson et al.(13,14)
investigated the effect of ARA on Δ5-desaturation and incorpo-
ration of 2H-labelled dihomo-γ-linolenic acid (DGLA; 20 : 3n-6)
into plasma lipids. Adult male subjects (n 4) were given diets
containing either 1·7 g/d ARA or 0·21 g/d ARA for 50 d. After
50 d, subjects were dosed with a mixture containing
2H-labelled ethyl esters of DGLA[d4] and oleic acid[d2], and a
series of blood samples were sequentially drawn over a 72-h
period. The estimated conversion of DGLA[d4] to ARA[d4] was
17·7 ± 0·8 %when subjects had been on the high ARA intake and
2·1 ± 1·4 % when subjects had been on the low ARA intake. The
concentrations of ARA[d4] in total plasma lipids from subjects
after the high and low ARA periods were 2·1 ± 0·6 and 0·3 ±
0·2 μmol/ml plasma/mmol of DGLA[d4] fed per kg of body
weight. These data indicate that conversion of DGLA[d4] to
ARA[d4] was stimulated 7- to 8-fold by the high ARA intake,
although a decrease in turnover of ARA in the high ARA group
cannot be excluded.
Effect of arachidonic acid on blood lipid concentrations
Roberts et al.(29) conducted a study in resistance-trained male
subjects and found that serum cholesterol concentrations were
not changed after ARA supplementation (1 g/d for 50 d).
Likewise, there were no changes in serum concentrations of
total, LDL- and HDL-cholesterol, TAG, apo AI, apo B or lipopro-
tein (a) after ARA supplementation in different study designs (see
Table 2) in adults(14,25,27) and schoolchildren(19,31).
Thus, from the available evidence it appears that increasing
ARA intake even up to 1·7 g/d does not affect blood lipid con-
centrations. However, there are few such studies and the effect
of ARA on blood lipids in dyslipidaemic subjects has not been
investigated.
Effect of arachidonic acid on blood pressure
In the study of Kusumoto et al.(25), blood pressure was not
affected by increasing ARA intake to 838 mg/d. Participants in
this studywere normotensive and there are no studies of increas-
ing ARA intake on blood pressure in hypertensive subjects.
Effect of arachidonic acid on platelet aggregation,
bleeding and haematological markers
In a randomised double-blind trial in Italian patients with liver
cirrhosis, Pantaleo et al.(28) compared the effects of 2 g/d ARA
from ARASCO for 8 weeks with those of oleic acid on colla-
gen-induced aggregation of platelet-rich plasma. Comparedwith
pre-study levels, platelet aggregation was significantly increased
in the ARA group, but not in the oleic acid group.
Kusumoto et al.(25) carried out a double-blind, placebo-
controlled study in healthy Japanese men consuming a high fish
diet. One group of men received capsules providing 838 mg
ARA incorporated into TAG (SUNTGA40S) daily for 4 weeks,
while another group received capsules with olive oil as control.
Collagen-, ARA- and ADP-induced aggregation of platelet-rich
plasmawere not affected byARA supplementation. Also, haema-
tological parameters (Hb concentration, packed cell volume,
erythrocyte numbers, total leucocytes, thrombocytes and mean
of corpuscular volume) and coagulation parameters (prothrom-
bin time and antithrombin III activity) remained unchanged.
In a single-blind cross-over study, healthy male volunteers
received 1·7 g/d or 0·2 g/d of ARA for 50 d(13). Aggregation
of platelet-rich plasma was induced using ADP, collagen,
and ARA. No effects of increased ARA intake were observed.
Also, platelet count, bleeding time, partial thromboplastin time
and antithrombin III concentrations remained unchanged.
Prothrombin time, however, was significantly lowered by about
10 % after ARA intake.
In a randomised double-blind study, resistance-trained male
subjects received either ARA (1 g/d) or maize oil as placebo for
50 d(29). There was no effect on erythrocyte numbers.
Most haematological parameters were not altered by
1500 mg/d ARA for 4 weeks in healthy young men(27).
Haematological parameters (Hb concentration, packed cell
volume, erythrocyte numbers, numbers of segmented neutro-
phils, eosinophils, basophils and platelets) were not changed in
a study with Egyptian schoolchildren who received ARA
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Fig. 5. Relationship between arachidonic acid (ARA) intake (mg/d) and incre-
ment inARA in serumor plasma phospholipids (as percentage of total fatty acids).
Data are taken fromHirota et al.(22), Ishikura et al.(23), Kakutani et al.(24) (two doses
of ARA used), Kusumoto et al.(25), Nelson et al.(14), Pantaleo et al.(28) and Thies
et al.(33). The line of best fit for these data points is shown.
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(10 mg/kg body weight per d) for 15 d (5 d over each of 3 con-
secutive weeks) with or without praziquantel, a medication used
to treat certain types of parasitic worm infection(19). Several coagu-
lation parameters (prothrombin concentration, international nor-
malised ratio and partial thromboplastin time) were also not
changed, although both prothrombin time and clotting time were
significantly shorter, although only by <2%(19). Comparable
results were found in a smaller study in older schoolchildren using
a similar design(31).
In summary, most studies report no effect of increased ARA
intake on platelet aggregation or coagulation parameters, and
no studies report effects on bleeding time. However, the study
that used the highest intake of ARA(28) reported enhanced
platelet aggregation. The early study of Seyberth et al.(12) using
6 g ARA per d also saw this effect. The effect of doses of
ARA of 2 g/d or more on platelet aggregation requires further
investigation.
Effect of arachidonic acid on biomarkers of immunity and
inflammation
Kelley et al.(15,16) reported data from a controlled, cross-over trial
in ten healthy adult men in the USA; this is the same study as
Nelson et al.(13,14). The participants consumed a standard diet
providing 0·21 g ARA per d or an intervention diet providing
1·7 g ARA per d for 50 d. ARA did not influence ex vivo lympho-
cyte proliferation in response to several agents or ex vivo natural
killer cell activity(15). Participants received the measles/mumps/
rubella and influenza vaccines: the ex vivo proliferation of lym-
phocytes in response to influenza vaccine was about 4-fold
higher in the group receiving 1·7 g ARA per d than in the low
ARA group(15). However, serum antibody titres against the influ-
enza vaccine were not affected by high ARA(16). Although the
total number of leucocytes was not affected, there were
significantly more blood granulocytes (mainly neutrophils)
when participants received 1·7 g ARA per d(15). However, blood
lymphocyte and monocyte numbers were not affected by
ARA(16). Ex vivo production of several inflammatory cytokines
in response to lipopolysaccharide was not different between
low and high ARA treatment(16). However, lipopolysaccharide-
stimulated production of PGE2 and leukotriene B4 was signifi-
cantly higher after high ARA than after the standard diet(16).
This probably reflects the higher ARA content of the cells
involved, although this was not reported.
Thies et al.(33–35) reported results from a placebo-controlled,
randomised, parallel study in healthy older British subjects: eight
participants received a blend of palm and sunflower seed oils as
control, while eight received approximately 700 mg ARA (from
ARASCO) daily for 12weeks. Participant’s habitual intake of ARA
was about 150 mg/d. Blood samples were collected at baseline
and at 4, 8 and 12weeks supplementation and then after 4weeks
washout. There was no effect of increased intake of ARA on the
numbers or percentages of different types of immune cells in the
blood, on ex vivo blood lymphocyte proliferation in response to
mitogenic stimulation, on ex vivo production of T-cell derived
cytokines or lipopolysaccharide-stimulated cytokines, on ex vivo
natural killer cell activity, on phagocytic activity and respiratory
burst of neutrophils and monocytes or on the plasma
concentrations of three different adhesion molecules(33–35).
This study clearly demonstrates that there is no strong impact
of approximately 700mg/d ARA on blood immune cell numbers,
on ex vivo markers of the immune response or on markers of
inflammation in healthy older subjects. The study did not mea-
sure concentrations or production of ARA-derived lipid media-
tors like prostaglandins.
Roberts et al.(29) saw no effect of 1 g ARA per d for 50 d
on total blood leucocyte numbers or types in resistance trained
men.
Schubert et al.(30) performed a study comparing a mix of FA
considered to be anti-inflammatory with ARA (40 mg/d) for 2
weeks in thirty healthy participants; an additional blood sample
was collected 2 weeks after stopping the intervention. Whole
blood was stimulated ex vivo with lipopolysaccharide and
appearance of PGE1 (produced from DGLA), PGE2, leukotriene
B4, TNF, IL-8 and IL-10 were measured. There were no signifi-
cant differences in any of these at the end of supplementation
compared with baseline in either group, and there were no sig-
nificant differences between the two groups at the end of the
supplementation period. However, some differences were seen
between groups 2 weeks after stopping the supplementation;
these are difficult to interpret.
Kakutani et al.(24) performed a double-blinded, parallel,
placebo-controlled intervention study with 118 healthy
Japanese elderly subjects. They received olive oil as control
or capsules providing approximately 240 mg or approximately
720 mg ARA per d for 4 weeks, followed by a 4-week washout
period. There was no impact of ARA on circulating concentra-
tions of C-reactive protein, IgE, two pro-inflammatory
cytokines (TNF and IL-6), PGE2 or lipoxin A4. The authors
concluded that there was no impact of 240 or 720 mg ARA daily
on inflammation.
In Egyptian schoolchildren infected with S. mansoni, ARA
(10 mg/kg body weight per d for 5 d in each of 3 weeks)
significantly decreased plasma IL-10 and interferon-γ concentra-
tions compared with study entry(19). However, these findings are
difficult to interpret because ARAwas able to effectively treat the
parasitic infection, and the altered plasma cytokines may simply
reflect reduced pathogen burden.
In summary, the available evidence suggests little or no
impact of increasing ARA intake by as much as 1·5 g/d on
immune function or on markers of inflammation, apart from a
small increase in ARA-derived eicosanoid production when cells
are stimulated. However, the health impact of the latter response
is not known.
Effect of arachidonic acid on cognitive function
Despite ARA having an important structural and functional role
in the brain(7), there are very few RCT of cognitive function in
humans where ARA is the sole intervention. Most intervention
studies involving ARA have been in combination with DHA
and have been undertaken during infancy.
Ishikura et al.(23) investigated the effects of ARA on age-
related event-related potentials in twenty-five healthy elderly
Japanese men. The study was performed using a double-blind
crossover design and the subjects were administered 240 mg/d
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of ARA from an ARA-enriched TAG (SUNTGA40S) in capsules or
the same amount of olive oil in capsules as placebo for 1 month.
Event-related potentials, which included P300 latency and
amplitude, were measured before capsule administration and
after 1 month of administration. In subjects administered ARA,
P300 latency was significantly shorter, and P300 amplitude
was significantly higher than in those administered olive oil cap-
sules. It was concluded that supplementation of ARAmay reduce
age-related decline in cognitive function and learning ability.
However, this is based upon a single small study and more
research is needed in this important area.
Effect of arachidonic acid on body composition, muscle
function and physical performance
Three double-blind RCT have reported outcomes of the effect of
ARA on body composition, muscle function and physical perfor-
mance(20,26,29). In the first study, thirty-one males from the USA
were randomly assigned to receive capsules providing either
1000 mg ARA or maize oil per d for 50 d. No significant effects
were found on body weight, fat free mass, fat mass, anabolic
hormones or intramuscular markers of muscle hypertrophy(29).
However, compared with baseline, ARA supplementation incre-
ased anaerobic peak power by 8·5 % at day 50. On day 25, the
ARA supplemented group had attenuated serum IL-6
levels whereas levels of serum PGE2, a potential ergogenic factor,
tended towards an increase. The authors suggested that ARA sup-
plementation would decrease inflammation (lower IL-6), thus
making intense training more tolerable. No support was found
for ARA to stimulate muscle hypertrophy, which would lead to
a greater strength gain and/or muscle mass due to training.
In the second study, thirty males from the USA were
randomised to receive either 600 mg ARA (from 1·5 g
ARASYN oil) or maize oil daily during an 8-week training
programme. The ARA group showed a significant increase in
lean body mass (2·9 %), upper body strength (8·7 %) and peak
power (12·7 %)(20). ARA supplementation was suggested to
increase post-exercise anabolic signalling rather than protein
synthesis in skeletal muscle.
Markworth et al.(27) conducted a 4-week RCT of 1500 mg/d
ARA in nineteen young males involved in a resistance training
programme. There was a significant reduction in fat mass
(–0·33 kg or –1·7 %) in the ARA group compared with the control
group (+0·49 kg or +3·8 %). There was no effect of ARA on lean
mass and effects of ARA on leg muscle volumewere small. Other
measurements in these individuals were reported by Mitchell
et al.(26): prior ARA supplementation did not alter the acute ana-
bolic response (i.e. muscle protein synthesis and anabolic signal-
ling in muscle) to resistance exercise in these trained men, and
the authors concluded that there is no link between ARA and
short-term anabolism. However, some muscle changes were
seen 48 h after completing the resistance exercise in men in
the ARA group.
In summary, two of these studies suggest that ARA can
improve peak power andmay have an effect on lean bodymass,
while a third study suggests that ARA has an effect on late
responses to resistance exercise. These effects and the underly-
ing mechanisms require further exploration.
Effect of arachidonic acid on urinary metabolites
Ferretti et al.(17) reported increased urinary levels of ARA metab-
olites (11-dehydro-thromboxane B2 and 2,3-dinor-6-oxo-PGF1)
following 1·7 g ARA per d for 50 d. Kidney diuretic function, both
normal and diuretic-stimulated, was not compromised in
patients with liver cirrhosis (aged >60 years) who consumed
2 g/d ARA for 8 weeks: urinary sodium and ARA metabolites
(i.e. PGE2, 6-keto-PGF1, 8-epi-PGF2 and 11-dehydro-thromboxane
B2) were similar to those observed in the placebo group(28).
More recently, with smaller dosages (240 or 720 mg ARA
per d), for a shorter duration (4 weeks) and on a back-
ground of high DHA and EPA intake levels, ARA metabolite
(11-dehydro-thromboxane B2, 2,3-dinor-6-keto-PGF1α and 9,15-
dioxo-11α-hydroxy-13,14-dihydro-2,3,4,5-tetranor-prostan-1,20-
dioic acid),) excretion in healthy Japanese elderly (>55 years
of age) was also found not to be affected compared with the
placebo (olive oil) group(24).
In summary, most studies report no effect of increased ARA
intake on urinary excretion of ARA metabolites, and one study
reports no effect of ARA on renal function in cirrhotic patients.
Summary and conclusions
The literature search identified twenty-two articles from four-
teen RCT of increasing ARA intake in humans. These studies
were published between 1997 and 2018. Most were conduc-
ted in adults. Studies in adults used between 40 and 2000 mg
ARA per d, were of 1–12 weeks duration and usually used
ARA as a supplement. Most studies used ARA intakes of
240–1000 mg/d. Only one study investigated more than one
dose of ARA(24). Many studies were conducted in healthy young
or older subjects, and several were restricted to men. One study
was conducted in breast-feeding women and one in patients
with liver cirrhosis. Few studies controlled the diet of the subjects
under study and few studies assessed background diet. A num-
ber of studies reported the effect of ARA on FA composition of
blood pools like lipids, erythrocytes and mononuclear cells, and
one study reported on breast milk FA and another on skeletal
muscle FA. Given the role of ARA-derived eicosanoids in regu-
lating inflammation, immune function, platelet aggregation and
blood clotting, it is not surprising that several studies investigated
the effect of ARA on these outcomes. In contrast, there have been
only few studies investigating effects on blood lipids, blood pres-
sure and cognition. Inmost of these areas, there are too few stud-
ies to draw firm conclusions on the impact of ARA. Furthermore,
the risk of bias was unclear for many of the studies, limiting the
robustness of their findings.
It is clear from the existing studies that ARA supplements
significantly increase the content of ARA in different blood
fractions with doses as low as 80 mg/d being effective. The
low dose of 40 mg ARA per d did not affect ARA level in plasma
and erythrocytes. It is likely that enrichment of ARA in different
compartments and pools is dose dependent, but may become
saturated at higher intakes. EPA was decreased in several studies
but DHAwas usually not affected by ARA supplementation, even
at the highest doses tested. Often incorporation of ARAwas at the
expense of LA. From the available evidence, it appears that
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increasing ARA intake does not affect blood lipid concentrations
or blood pressure. However, there are few such studies and the
effect of ARA on blood lipids in dyslipidaemic subjects or on
blood pressure in hypertensive subjects has not been investi-
gated. Furthermore, most studies have reported no effect of
increased ARA intake on platelet aggregation or coagulation
parameters and no studies have seen effects on bleeding time.
However, one study that used the highest intake of ARA(28)
reported enhanced platelet aggregation and this requires further
investigation. The available evidence from rather detailed studies
suggests little or no impact of increasing ARA intake by as much
as 1·5 g/d on immune function or on markers of inflammation,
apart from a small increase in ARA-derived eicosanoid produc-
tion when immune cells are stimulated. However, the effect of
the latter response is not known. Several studies report no effect
of increased ARA intake on urinary excretion of ARAmetabolites.
One study concluded that supplementation with ARA may
reduce age-related decline in cognitive function and learning
ability. This could be an important effect and more research
should be conducted in this area. Another interesting observation
is the improvement in peak power and lean body mass seen in
young adults undergoing exercise training. Again these effects
need further investigation along with exploration of the likely
mechanisms. It is important to note that none of the studies
included here was of more than 12 weeks duration, and most
were shorter than this; this may be insufficient time to affect sev-
eral of the outcomes assessed such as cognitive function, body
composition and physical performance.
Thus, overall there seem to be few marked benefits of in-
creasing ARA intake from the typical intake of 100–200 mg/d
to as much as 1000 mg/d or perhaps even more. However,
the suggested impacts on cognitive and muscle function may
both be important, particularly in the ageing population, and
therefore the effect of higher intakes of ARA is deserving of
further study. The studies reviewed herein suggest no adverse
effects of increased ARA intake up to at least 1000–1500 mg/d
on blood lipids, platelet aggregation and blood clotting, immune
function, inflammation or urinary excretion of ARA metabolites.
However, in many areas there are insufficient studies to make
firm conclusions. Based on the RCT reviewed, there are not
enough data to make any recommendations for specific health
effects of ARA intake.
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